Search
Conivaptan
go.drugbank.com/drugs/DB00872ApprovedIt was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).
Mineral oil
go.drugbank.com/drugs/DB11057ApprovedInvestigationalVet approvedIt is also used as a mild laxative for human or veterinary uses. … Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum.
Mixtures: Mizon Collagenic Aqua Volume Up Li P Essence RenewalCategories: Drugs for ConstipationGlutathione
go.drugbank.com/drugs/DB00143ApprovedInvestigationalNutraceuticalIt conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Indomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigationaleffect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for … Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, [A486] along with other acetic acid derivatives such as [diclofenac]
Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical UseVepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508, A275509] On May 1, 2026, the FDA granted approval for vepdegestrant tablets under the trade name VEPPANU. … [A275508] Specifically, vepdegestrant is being developed as a first-line or subsequent treatment option for patients whose tumors grow in response to estrogen and have progressed after standard therapies
Encainide
go.drugbank.com/drugs/DB01228ApprovedWithdrawnThe manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Colestipol
go.drugbank.com/drugs/DB00375Approvedbiliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. … [FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaDapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigationalDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. … [L48251] It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April
Trichlormethiazide
go.drugbank.com/drugs/DB01021ApprovedVet approvedA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)